Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive

Posts in: video (3)

Slack Capital: EXOZ investment report and CEO interview
heltzeninvestorpress clippingsvideo
Slack Capital: EXOZ investment report and CEO interviewMay 13, 2025
AI transforming biotechnology: From form with AlphaFold to function with exozymes
investorvideoscience
AI transforming biotechnology: From form with AlphaFold to function with exozymesApril 28, 2025
Dr. Tyler Korman, co-founder and VP of Research at eXoZymes, is excited about the 'exozymes' cover story in GEN Biotechnology, which is freely available as an Open Access paper.
press releaseinvestorvideoscience
GEN Biotechnology cover story: Bringing clarity and precision to the cell-free space by introducing exozymesApril 21, 2025
Bloomberg TV: Jane King interviews co-founder and VP of Research, Dr. Tyler Korman
investorpress clippingsvideoscience
Bloomberg TV: Jane King interviews co-founder and VP of Research, Dr. Tyler KormanApril 15, 2025
ARCHIVE: eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO
talentpress releaseinvestorvideoARCHIVE
ARCHIVE: eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCOApril 2, 2025
ARCHIVE: Fox Business: Interview with Chief Market Strategist, Lou Basenese
investorpress clippingsvideoARCHIVE
ARCHIVE: Fox Business: Interview with Chief Market Strategist, Lou BaseneseMarch 17, 2025
ARCHIVE: Fox Business: Interview with CEO Michael Heltzen
heltzeninvestorpress clippingsvideoARCHIVE
ARCHIVE: Fox Business: Interview with CEO Michael HeltzenMarch 3, 2025
ARCHIVE: Watch eXoZymes' Nasdaq closing bell ceremony
heltzeninvestorvideoARCHIVE
ARCHIVE: Watch eXoZymes' Nasdaq closing bell ceremonyFebruary 20, 2025
ARCHIVE: Creating value for partners through exozyme biosolutions
investorvideo
ARCHIVE: Creating value for partners through exozyme biosolutionsFebruary 12, 2025
ARCHIVE: The difference between enzymes and exozymes: Explaining our tech
investorvideoARCHIVE
ARCHIVE: The difference between enzymes and exozymes: Explaining our techFebruary 12, 2025
Previous page
Page 3 of 5
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark